559 related articles for article (PubMed ID: 2581135)
1. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
[TBL] [Abstract][Full Text] [Related]
2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
Jenner P; Marsden CD
J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
[TBL] [Abstract][Full Text] [Related]
3. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
4. The clinical syndrome of striatal dopamine deficiency: parkinsonism induced by MPTP.
Eldridge R; Rocca WA
N Engl J Med; 1985 Oct; 313(18):1159-60. PubMed ID: 3876508
[No Abstract] [Full Text] [Related]
5. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
Lange KW
Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
[TBL] [Abstract][Full Text] [Related]
6. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
[TBL] [Abstract][Full Text] [Related]
7. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Widner H; Tetrud J; Rehncrona S; Snow B; Brundin P; Gustavii B; Björklund A; Lindvall O; Langston JW
N Engl J Med; 1992 Nov; 327(22):1556-63. PubMed ID: 1435882
[TBL] [Abstract][Full Text] [Related]
8. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
[TBL] [Abstract][Full Text] [Related]
9. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
Altagracia M; Rojas P; Kravzov J; Rios C
Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
[No Abstract] [Full Text] [Related]
10. MPTP: a pharmacological tool to study parkinsonism.
Kulkarni SK; Mehta AK; Aley KO; Shukla VK
Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
Miyoshi R; Kito S; Ishida H; Katayama S
Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
[TBL] [Abstract][Full Text] [Related]
12. 6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.
Doudet DJ; Wyatt RJ; Cannon-Spoor E; Suddath R; McLellan CA; Cohen RM
J Neural Transplant Plast; 1993; 4(1):27-38. PubMed ID: 7509198
[TBL] [Abstract][Full Text] [Related]
13. Saccade responses to dopamine in human MPTP-induced parkinsonism.
Hotson JR; Langston EB; Langston JW
Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
[TBL] [Abstract][Full Text] [Related]
14. Chronic exposure to MPTP as a primate model of progressive parkinsonism: a pilot study with a free radical scavenger.
Blanchet PJ; Konitsiotis S; Hyland K; Arnold LA; Pettigrew KD; Chase TN
Exp Neurol; 1998 Oct; 153(2):214-22. PubMed ID: 9784281
[TBL] [Abstract][Full Text] [Related]
15. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
[TBL] [Abstract][Full Text] [Related]
16. Selective alterations of gene expression in mice induced by MPTP.
Xu Z; Cawthon D; McCastlain KA; Slikker W; Ali SF
Synapse; 2005 Jan; 55(1):45-51. PubMed ID: 15499605
[TBL] [Abstract][Full Text] [Related]
17. [Study of extracellular concentration of dopamine and its metabolites in mice striatum by a microdialysis technique at intraperitoneal administration of MPTP].
Averkin RG; Korshunov VA; Shchegolevskiĭ NV; Mats VN; Markevich VA; Grigor'ian GA; Bazian AS
Zh Vyssh Nerv Deiat Im I P Pavlova; 2010; 60(1):109-19. PubMed ID: 20352690
[TBL] [Abstract][Full Text] [Related]
18. MPTP-induced model of Parkinson's disease in cytochrome P450 2E1 knockout mice.
Viaggi C; Vaglini F; Pardini C; Caramelli A; Corsini GU
Neuropharmacology; 2009 Jun; 56(8):1075-81. PubMed ID: 19298832
[TBL] [Abstract][Full Text] [Related]
19. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
Matsubara K
Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
[TBL] [Abstract][Full Text] [Related]
20. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
